Israel Healthcare Ventures

Hadar Ron founded IHCV in 2000. She is both a medical doctor and an attorney by training, and worked as legal counsel and corporate secretary at Teva Pharmaceuticals before launching the firm. Her clinical and regulatory experience directly informs the firm's investment thesis and post-investment support for portfolio companies navigating FDA and CE-mark approvals.

IHCV focuses on seed and early-stage healthcare companies. The firm typically leads or co-leads financing rounds and takes an active board role to help guide clinical and regulatory strategy during the critical development phase prior to commercialization.

IHCV invests across medical devices, biotechnology, digital health, and healthcare services. The firm does not invest in healthcare IT or health-tech platforms unrelated to regulated medical outcomes, nor does it participate in later-stage, pre-IPO rounds that are outside its core early-stage mandate.

IHCV sources its deal flow primarily from Israeli research institutions, hospitals, and the local start-up ecosystem. Portfolio companies are typically Israeli-founded, but their target markets and clinical trial pathways are US and Europe-focused. The firm does not actively source primary deals outside Israel.

The firm draws on Hadar Ron's deep relationships with Israeli medical research centers, including the Weizmann Institute and the Technion, as well as her role as a co-founder of the Israel Life Science Industry organization. This network provides early visibility into technology spinouts and clinician-founded start-ups before they reach the broader venture market.